Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients

Treatment of anaemia is a very important aspect in the management of cancer patients. In order to carry out a consensus process about the use of erythropoietic stimulating agents (ESAs) in cancer patients, the Spanish Society of Medical Oncology (SEOM) elaborated a working group which coordinated a...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical & translational oncology Vol. 11; no. 11; pp. 727 - 736
Main Authors:	Alberola Candel, Vicente, Carrato Mena, Alfredo, Díaz-Rubio García, Eduardo, Gascón Vilaplana, Pere, González Barón, Manuel, Martín Jiménez, Miguel, Alba Conejo, Emilio, Cassinello Espinosa, Javier, Colomer, Ramon, Cruz Hernández, Juan Jesús, Barnadas i Molins, Agustí, Camps Herrero, Carlos, Casas Fernández de Tejerina, Ana Ma, Carulla Torrent, Joan, Constenla Figueiras, Manuel, Gavilá Gregori, Joaquin, Isla Casado, Ma. Dolores, Massuti Sureda, Bartomeu, Provencio Pulla, Mariano, Rodríguez Sánchez, César Augusto, Sanz Ortiz, Jaime
Format:	Journal Article
Language:	English
Published:	Milan Springer Milan 01-11-2009
Subjects:	Anemia - complications Anemia - drug therapy Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Blood Transfusion Chronic Disease - therapy Clinical Trials as Topic Educational Series Erythrocytes - metabolism Hematinics - therapeutic use Hemoglobins - metabolism Humans Iron - metabolism Medical Oncology - methods Medicine Medicine & Public Health Neoplasms - complications Oncology Practice Guidelines as Topic Spain Spain Erythropoietic stimulating agents Chemotherapy Cancer-associated anaemia Update Consensus
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Treatment of anaemia is a very important aspect in the management of cancer patients. In order to carry out a consensus process about the use of erythropoietic stimulating agents (ESAs) in cancer patients, the Spanish Society of Medical Oncology (SEOM) elaborated a working group which coordinated a panel of medical oncology specialists. This working group has reviewed the main issues about the use of ESAs. In addition a consensus meeting was held in Madrid on 25 April 2007. The following conclusions were made: Since ESA treatment increases the haemoglobin (Hb) level and decreases the red blood cell (RBC) transfusion requirements, ESAs should be used within the approved indications in patients undergoing chemotherapy treatment, beginning at a Hb level below 11 g/dl and maintaining it around 12 g/dl, with iron supplements if necessary. Neither increasing the ESA dose in non-responders nor the use of ESAs in the treatment of chronic cancer-related anaemia is recommended.
ISSN:	1699-048X 1699-3055
DOI:	10.1007/s12094-009-0435-6